Actively Recruiting
Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
Led by Sun Yat-sen University · Updated on 2026-04-06
220
Participants Needed
3
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase 3, randomized, controlled clinical trial comparing two brain-directed treatment strategies for adult patients with extensive brain metastases from lung adenocarcinoma. The trial compares fractionated stereotactic radiotherapy combined with bevacizumab (FSRT-Bev) versus hippocampus-avoidant whole-brain radiotherapy with simultaneous integrated boost (HA-WBRT-SIB). The main objectives are to evaluate intracranial tumor control and preservation of neurocognitive function . Patients will be randomly assigned in a 1:1 ratio to receive either FSRT plus bevacizumab or HA-WBRT-SIB. In the experimental group, FSRT is delivered to visible brain tumors over 5 daily treatments (total 30 Gy, 6 Gy per fraction). Bevacizumab is given intravenously every 3 weeks for 4 cycles. In the control group, patients receive hippocampus-avoidant whole-brain radiation (25 Gy) with a simultaneous dose boost to metastatic lesions (40 Gy total) over 10 daily treatments.
CONDITIONS
Official Title
Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Pathologically confirmed non-squamous non-small cell lung cancer (adenocarcinoma)
- Extensive brain metastases defined as 1-2 metastases with at least one 3 cm or larger; or 3-10 metastases with at least one 2 cm or larger; or 11-20 metastases
- Stable extracranial disease
- ECOG performance status of 0 to 2
- Adequate bone marrow, liver, and kidney function
- Provided written informed consent
You will not qualify if you...
- Contraindications to bevacizumab such as uncontrolled hypertension, history of bleeding or blood clots, recent surgery
- Presence of leptomeningeal metastasis
- Previous brain radiotherapy or brain metastases surgery
- Severe mass effect requiring urgent neurosurgery
- Severe cardiovascular, vascular, or gastrointestinal disease within the last 6 months
- Proteinuria of 3+ or urine protein over 1 gram in 24 hours
- Other active cancers except curable non-melanoma skin cancer or cervical carcinoma in situ
- Unable to comply with neurocognitive testing
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400016
Actively Recruiting
2
Sun yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
3
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Guangzhou, Guangdong, China, 510405
Actively Recruiting
Research Team
H
Hui Liu
CONTACT
B
Bo Qiu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here